Answers are grounded in this paper and cite their sources.
Glucolipid metabolic disorders (GLMDs) are chronic metabolic diseases with complex pathogenesis and limited therapeutic options. Exosome-like nanovesicles derived from medicinal and edible plants (PELNVs) have emerged as promising natural nanoplatforms owing to their edible safety, bioactive cargos, and delivery potential. This review summarizes recent advances in PELNV-based interventions for GLMDs, focusing on their physicochemical properties, biogenesis, molecular composition, isolation strategies, source-dependent functional bias, oral delivery, and engineering potential. Accumulating evidence indicates that PELNVs may regulate metabolic inflammation and oxidative stress, improve insulin resistance and glucose homeostasis, modulate hepatic lipid deposition, remodel the gut barrier–microbiota–host metabolic axis, and promote the repair of complications associated with GLMDs, such as diabetic wounds. However, source heterogeneity, insufficient quality-control standards, limited pharmacokinetic data, and scarce clinical evidence remain major challenges. Further mechanistic clarification, standardization, and translational validation are required to support future biomedical applications of PELNVs.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: